Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Keytruda = $265,000 (17 doses per year)

<< Previous

Bullboard Posts

Next >>

Comment by N0taP00pon Apr 14, 2023 1:51am

149 Views

Post# 35394557

RE:RE:RE:RE:RE:Keytruda = $265,000 (17 doses per year)

Thank you, Slayer. So even though there are three other drugs out there for this unmet need, as long as the efficacy and safety are good and the duration is equal or better, the total numbers may not matter. Plus add in the convenience and cost factor. Everything seems to align. Two more weeks (out of 500 weeks of holding) will require extra patience.

<< Previous

Bullboard Posts

Next >>

AI companies to invest in